MedTrace Logo

Testing Spectrosense EVA System for Detection of Pancreatic Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air

NCT01994681 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2013-12-05

No results posted yet for this study

Summary

Volatile Organic Compounds (VOC) in human breath are captured and analyzed by the Spectrosense EVA system, which is combination of a gas chromatography (GC) and software algorithm. The objective is to obtain a set or sets of VOC bio-markers that will provide the best discrimination between Pancreatic Cancer sick population and healthy population. The gold standard for identifying sick/healthy population is biopsy proven Pancreatic cancer.

Conditions

Sponsors & Collaborators

  • Spectrosense Ltd.

    collaborator INDUSTRY

  • Rauscher, Gregory E., M.D. PA

    lead INDIV

Principal Investigators

  • Martin Gutierrez, MD · Hackensack Meridian Health

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01994681 on ClinicalTrials.gov